SG11201808906RA - Compositions and methods of vaccination against dengue virus in children and young adults - Google Patents
Compositions and methods of vaccination against dengue virus in children and young adultsInfo
- Publication number
- SG11201808906RA SG11201808906RA SG11201808906RA SG11201808906RA SG11201808906RA SG 11201808906R A SG11201808906R A SG 11201808906RA SG 11201808906R A SG11201808906R A SG 11201808906RA SG 11201808906R A SG11201808906R A SG 11201808906RA SG 11201808906R A SG11201808906R A SG 11201808906RA
- Authority
- SG
- Singapore
- Prior art keywords
- dengue
- virus
- compositions
- international
- den
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
- C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322167P | 2016-04-13 | 2016-04-13 | |
| PCT/IB2017/052160 WO2017179017A1 (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808906RA true SG11201808906RA (en) | 2018-11-29 |
Family
ID=58671740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808906RA SG11201808906RA (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
| SG10201913383RA SG10201913383RA (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913383RA SG10201913383RA (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11007261B2 (https=) |
| EP (1) | EP3442571A1 (https=) |
| JP (3) | JP2019511533A (https=) |
| KR (1) | KR102611235B1 (https=) |
| CN (2) | CN109069615B (https=) |
| AU (2) | AU2017250696A1 (https=) |
| BR (1) | BR112018071087A2 (https=) |
| CA (1) | CA3020484A1 (https=) |
| CO (1) | CO2018011355A2 (https=) |
| MX (1) | MX2018012459A (https=) |
| MY (1) | MY192806A (https=) |
| PH (1) | PH12018502175B1 (https=) |
| SG (2) | SG11201808906RA (https=) |
| WO (1) | WO2017179017A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| TWI766876B (zh) * | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| WO2019112921A1 (en) * | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| MX2022001742A (es) * | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| EP4357464A1 (en) * | 2022-10-20 | 2024-04-24 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| WO2024097725A1 (en) * | 2022-11-02 | 2024-05-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
| EP4375381B1 (en) | 2022-11-18 | 2026-02-25 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| CN120529951A (zh) | 2022-11-29 | 2025-08-22 | 武田疫苗股份有限公司 | 大规模黄病毒疫苗生产和制造 |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481982T1 (de) * | 2002-05-03 | 2010-10-15 | Us Gov Health & Human Serv | Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. |
| NZ597000A (en) | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| EP2771366A4 (en) * | 2011-10-25 | 2015-06-03 | Florida Gulf Coast University Board Of Trustees | VACCINES AND METHOD FOR PRODUCING A VACCINE FOR INDUCING IMMUNITY AGAINST ALL SERGENT TYPES OF THE DENGUE VIRUS |
| NZ630831A (en) * | 2012-06-10 | 2019-02-22 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| MX381497B (es) * | 2012-07-24 | 2025-03-12 | Sanofi Pasteur | Composiciones vacuna. |
| TW201920677A (zh) * | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| JP2016504315A (ja) | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| HRP20231581T1 (hr) * | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2017
- 2017-04-13 US US16/093,385 patent/US11007261B2/en active Active
- 2017-04-13 MY MYPI2018001735A patent/MY192806A/en unknown
- 2017-04-13 CN CN201780028507.XA patent/CN109069615B/zh active Active
- 2017-04-13 WO PCT/IB2017/052160 patent/WO2017179017A1/en not_active Ceased
- 2017-04-13 MX MX2018012459A patent/MX2018012459A/es unknown
- 2017-04-13 SG SG11201808906RA patent/SG11201808906RA/en unknown
- 2017-04-13 SG SG10201913383RA patent/SG10201913383RA/en unknown
- 2017-04-13 AU AU2017250696A patent/AU2017250696A1/en not_active Abandoned
- 2017-04-13 PH PH1/2018/502175A patent/PH12018502175B1/en unknown
- 2017-04-13 CN CN202510170711.1A patent/CN120392993A/zh active Pending
- 2017-04-13 CA CA3020484A patent/CA3020484A1/en active Pending
- 2017-04-13 EP EP17721858.3A patent/EP3442571A1/en active Pending
- 2017-04-13 JP JP2018553428A patent/JP2019511533A/ja active Pending
- 2017-04-13 KR KR1020187032733A patent/KR102611235B1/ko active Active
- 2017-04-13 BR BR112018071087-3A patent/BR112018071087A2/pt active Search and Examination
-
2018
- 2018-10-24 CO CONC2018/0011355A patent/CO2018011355A2/es unknown
- 2018-11-19 AU AU2018267542A patent/AU2018267542B2/en active Active
-
2021
- 2021-04-13 US US17/229,109 patent/US20210236620A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069423A patent/JP2022089964A/ja active Pending
-
2024
- 2024-03-21 JP JP2024044760A patent/JP2024071463A/ja not_active Withdrawn
- 2024-08-30 US US18/821,030 patent/US20250235522A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018071087A2 (pt) | 2019-02-26 |
| US11007261B2 (en) | 2021-05-18 |
| MX2018012459A (es) | 2019-06-06 |
| SG10201913383RA (en) | 2020-03-30 |
| CN109069615B (zh) | 2025-03-04 |
| AU2018267542B2 (en) | 2020-06-18 |
| KR102611235B1 (ko) | 2023-12-08 |
| KR20180137514A (ko) | 2018-12-27 |
| AU2018267542A1 (en) | 2018-12-13 |
| JP2022089964A (ja) | 2022-06-16 |
| PH12018502175B1 (en) | 2023-12-06 |
| WO2017179017A1 (en) | 2017-10-19 |
| AU2017250696A1 (en) | 2018-11-22 |
| CN109069615A (zh) | 2018-12-21 |
| PH12018502175A1 (en) | 2019-10-28 |
| US20250235522A1 (en) | 2025-07-24 |
| CN120392993A (zh) | 2025-08-01 |
| EP3442571A1 (en) | 2019-02-20 |
| CO2018011355A2 (es) | 2018-11-13 |
| JP2024071463A (ja) | 2024-05-24 |
| MY192806A (en) | 2022-09-09 |
| US20190381163A1 (en) | 2019-12-19 |
| JP2019511533A (ja) | 2019-04-25 |
| US20210236620A1 (en) | 2021-08-05 |
| CA3020484A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808906RA (en) | Compositions and methods of vaccination against dengue virus in children and young adults | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201810549TA (en) | Hiv vaccine formulation | |
| SG11201804496UA (en) | Recombinant zika vaccines | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201805229YA (en) | Means and methods for treating hbv | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909606RA (en) | Probiotic molecules for reducing pathogen virulence | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201903893PA (en) | Synthetic chimeric poxviruses | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| ATE419006T1 (de) | Multivalenter dengue-virus impfstoff | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808809PA (en) | Therapeutic hpv vaccine combinations |